Thomas Eigentler
Thomas Eigentler
Dept. of Dermatology, University Hospital Tübingen
Verified email at
Cited by
Cited by
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial
A Ribas, I Puzanov, R Dummer, D Schadendorf, O Hamid, C Robert, ...
The lancet oncology 16 (8), 908-918, 2015
Systematic review of medical treatment in melanoma: current status and future prospects
C Garbe, TK Eigentler, U Keilholz, A Hauschild, JM Kirkwood
The oncologist 16 (1), 5, 2011
Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy
L Hofmann, A Forschner, C Loquai, SM Goldinger, L Zimmer, S Ugurel, ...
European journal of cancer 60, 190-209, 2016
Epidemiology of skin cancer
U Leiter, T Eigentler, C Garbe
Sunlight, vitamin D and skin cancer, 120-140, 2014
Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomised clinical trials
TK Eigentler, UM Caroli, P Radny, C Garbe
The lancet oncology 4 (12), 748-759, 2003
The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network
CJ Voskens, SM Goldinger, C Loquai, C Robert, KC Kaehler, C Berking, ...
PloS one 8 (1), e53745, 2013
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
L Zimmer, SM Goldinger, L Hofmann, C Loquai, S Ugurel, I Thomas, ...
European journal of cancer 60, 210-225, 2016
Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab
A Martens, K Wistuba-Hamprecht, MG Foppen, J Yuan, MA Postow, ...
Clinical Cancer Research 22 (12), 2908-2918, 2016
Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy
TK Eigentler, JC Hassel, C Berking, J Aberle, O Bachmann, V Grünwald, ...
Cancer treatment reviews 45, 7-18, 2016
Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients
B Weide, S Pascolo, B Scheel, E Derhovanessian, A Pflugfelder, ...
Journal of immunotherapy 32 (5), 498-507, 2009
Diagnosis and treatment of cutaneous melanoma: state of the art 2006
C Garbe, TK Eigentler
Melanoma research 17 (2), 117-127, 2007
Malignant melanoma S3‐guideline “diagnosis, therapy and follow‐up of melanoma”
A Pflugfelder, C Kochs, A Blum, M Capellaro, C Czeschik, T Dettenborn, ...
JDDG: Journal der Deutschen Dermatologischen Gesellschaft 11 (s6), 1-116, 2013
Age and gender are significant independent predictors of survival in primary cutaneous melanoma
K Lasithiotakis, U Leiter, F Meier, T Eigentler, G Metzler, M Moehrle, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2008
Results of the first phase I/II clinical vaccination trial with direct injection of mRNA
B Weide, JP Carralot, A Reese, B Scheel, TK Eigentler, I Hoerr, ...
Journal of immunotherapy 31 (2), 180-188, 2008
Prospective comparison of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced malignant …
C Pfannenberg, P Aschoff, S Schanz, SM Eschmann, C Plathow, ...
European Journal of Cancer 43 (3), 557-564, 2007
Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases
P Radny, UM Caroli, J Bauer, T Paul, C Schlegel, TK Eigentler, B Weide, ...
British journal of cancer 89 (9), 1620-1626, 2003
The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003
KG Lasithiotakis, U Leiter, R Gorkievicz, T Eigentler, H Breuninger, ...
Cancer 107 (6), 1331-1339, 2006
Prognostic factors of thin cutaneous melanoma: an analysis of the central malignant melanoma registry of the German Dermatological Society
U Leiter, PG Buettner, TK Eigentler, C Garbe
Journal of clinical oncology 22 (18), 3660-3667, 2004
Adjuvant low-dose interferon α2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional …
C Garbe, P Radny, R Linse, R Dummer, R Gutzmer, J Ulrich, R Stadler, ...
Annals of Oncology 19 (6), 1195-1201, 2008
Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions
JC Hassel, L Heinzerling, J Aberle, O Bähr, TK Eigentler, MO Grimm, ...
Cancer treatment reviews 57, 36-49, 2017
The system can't perform the operation now. Try again later.
Articles 1–20